The addition of iStent inject, an ab interno trabecular micro-bypass device, to cataract surgery reduced ocular hypotensive medication usage among patients with glaucoma, according to a study published in Ophthalmology Glaucoma.
The aim of the study was “to assess the efficacy for lowering IOP, reducing glaucoma medication and improving quality of life outcomes at 2 years following the implantation of the second-generation trabecular micro-bypass stent system in patients with mild to moderate open angle glaucoma and cataract in a tertiary Australian population,” Jennifer C. Fan